HIV

Gilead shelved safer HIV virus drugs for years to prevent its TDF monopoly, another grievance tells

SUBSCRIBE NOWThe patients tell Gilead concealed knowledge which TDF drugs tote kidney & bone dangers. TAF drugs wouldn't come out for many further years. In a motion to dismiss the Former suit, Gilead lawyers said the Inc. had "no duty" to advance newer drugs "on any particular timetable." The plaintiffs allege which the drugmaker didn't release TAF earlier because it would have reduced the marketability of its patent-prevented TDF drugs. "By hiding study about TAF's superior security profile & efficacy, & by continuing to downplay the dangers associated by TDF, Gilead continued its scheme to mislead the public & maximize profits for TDF," the grievance states.


Patients sue Gilead, telling drug Inc. intentionally delayed safer HIV virus medicine

The lawsuits tell that Gilead knew while Viread was confirmed in 2001 that it had to be given in high doses to be efficient, that meant it can damage the kidneys & bones. Yet the Inc. failed to adequately disclose those Risks in the medicine's label, the lawsuits tell.

Patients sue Gilead, saying drug company intentionally delayed safer HIV medicine

Patients sue Gilead over alleged delays in emerging safer HIV virus therapy

referring to Patients sue Gilead over alleged delays in emerging safer HIV virus medicationTwo California men filed a grievance versus drugmaker Gilead Sciences probably eight, claiming they were harmed because the pharmaceutical Inc. intentionally delayed the Growth of a safer version of tenofovir — its lead HIV virus therapy, reports the Los Angeles Times. The grievance alleges Gilead executives knew the Inc.'s scholars developed a less-toxic form of tenofovir as early as 2000. The HIV virus therapy poses dangers to patients' kidneys & bones. The grievance appeals HIV virus patients suffered from as many as ten years of "extra accumulated kidney & bone toxicity" as the Inc. saved the safer version on a shelf in its laboratory. The 2 men filed a parallel status which seeks class action status for patients who took the therapy from Oct. 26, 2001, until the present.




collected by :Lucy William
Comments